Hepatitis C News and Research

Latest Hepatitis C News and Research

Shared needle at school science experiment puts students at risk

In a science experiment at a Tasmanian Dover District high school, a teacher took blood samples from grade 9 and 10 students using the same needle. They were testing blood pH levels. Now students are being tested for HIV infection. The needle was dipped in methylated spirits each time before pricking but authorities say this is not enough to prevent transmission of HIV and other viruses like Hepatitis B and C.

8 Sep 2010

Phase 3 REALIZE study shows milestone in treatment development for hepatitis C

Vertex Pharmaceuticals Incorporated today announced that 65% of people overall achieved a sustained viral response (SVR or viral cure) with a telaprevir-based regimen in the pivotal Phase 3 REALIZE study, as compared to 17% of people in the control arm who received pegylated-interferon and ribavirin alone.

8 Sep 2010

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene Euronext, a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that they have entered into an exclusive partnership to develop and commercialize JX-594 for the treatment of solid tumors in Europe, the Commonwealth of Independent States (CIS) and the Middle East.

8 Sep 2010

Bristol-Myers Squibb signs definitive agreement to acquire ZymoGenetics

Bristol-Myers Squibb Company and ZymoGenetics, Inc. announced today that the companies have signed a definitive agreement providing for the acquisition of ZymoGenetics by Bristol-Myers Squibb, for $9.75 per share in cash.

8 Sep 2010

Teleflex partners with Access Scientific to distribute The PICC WAND vascular access device

Teleflex has partnered with Access Scientific Incorporated, San Diego, California to become the U.S. distributor of The PICC WAND™ Safety Introducer with ARROW® peelable sheath. This new, all- in-one vascular access device provides clinicians a faster, safer, simpler way to insert a peel away sheath for PICC or Midline catheter placements.

7 Sep 2010

Idenix Pharmaceuticals receives clinical hold order from FDA for IDX184, IDX320 programs

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the company received verbal notice on Friday, September 3, 2010 from the U.S. Food and Drug Administration (FDA) that the IDX184 and IDX320 programs have been placed on clinical hold.

7 Sep 2010

DSM, PolyTherics enter agreement for HiPEG IFN alpha-2a product development

DSM BioSolutions, DSM's microbial fermentation CMO business unit and PolyTherics Limited an innovator in precision engineering of proteins, today announced that they have entered into an agreement for the process development and manufacture of PolyTherics' lead biobetter product, HiPEG IFN alpha-2a.

7 Sep 2010

Researchers complete INX-189 clinical trials for Hepatitis C virus

The first clinical trials on a new investigational drug being developed to treat infections caused by Hepatitis C virus have been successfully completed.

3 Sep 2010

Regional Director of WHO Africa warns of impact global financial situation will have on health systems, MDGs

Regional Director of WHO for Africa Luis Sambo discussed during the 60th session of the Africa Committee of the WHO how the global economic situation could impact funding for health programs in Africa and the ability for countries to reach U.N. Millennium Development Goal targets, PANA/Afrique en ligne reports.

3 Sep 2010

Inhibitex completes INX-189 Phase1a trial for HCV

Inhibitex, Inc., announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo. The Company plans to present detailed results from this trial during a future scientific meeting.

2 Sep 2010

Unitract Tuberculin syringe clears FDA 510k market clearance

Unilife Corporation, today announced that its Unitract Tuberculin (TB) Syringe has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA).

2 Sep 2010

Abbott RealTime HBV assay receives marketing approval from FDA

Abbott announced today it has received approval from the U.S. Food and Drug Administration to market the Abbott RealTime HBV assay for measuring viral load or the amount of hepatitis B virus in a patient's blood. It is the first and only approved test capable of automating HBV viral load testing from sample extraction to final results.

2 Sep 2010

Media examine floods' impact in Pakistan

News outlets reported on the effects of major flooding in Pakistan and described the situation on the ground.

2 Sep 2010

Greater clarity on legal implications of testing incapacitated patients for blood-borne viruses needed

Anaesthetists are calling for greater clarity on the legal implications of testing incapacitated patients for blood-borne viruses, after a survey found that this is often done following staff needlestick injuries, in possible breach of UK legislation.

31 Aug 2010

Revolutions Medical seeks due recognition for RevVac vacuum operated auto retractable safety syringe

Revolutions Medical Corporation has notified the MDEA that there had been an error in awarding the Free Vac syringe the 2010 Medical Design Excellence Award when in fact Free Vac misrepresented ownership of the syringe. The syringe was actually Revolutions Medical Corporation's RevVac auto retractable safety syringe.

30 Aug 2010

Biomagnetics to acquire Lanzhou New Sunshine Plastics Industry

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the signing of a Letter of Intent (LOI) with Lanzhou New Sunshine Plastics Industry LTD. This expected acquisition is the fourth planned acquisition targeted at a share price of US $1.50 for Biomagnetics Diagnostics' common shares.

30 Aug 2010

Biomagnetics Diagnostics to acquire Hubei Tianyuan Chemical

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the signing of a Letter of Intent (LOI) with Hubei Tianyuan Chemical Co., Ltd. of Yangxin Nacheng Chemical Industry Zone, located in Hubei Province, China.

27 Aug 2010

FDA accepts Sanofi Pasteur's Menactra vaccine sBLA for active immunization of infants and toddlers

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for use of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) for active immunization of infants and toddlers for the prevention of invasive meningococcal disease caused by serogroups A, C, Y, and W-135.

26 Aug 2010

ZymoGenetics completes enrollment in Phase 2b PEG-IFN lambda clinical trial

ZymoGenetics, Inc. today announced enrollment has been completed in the Phase 2b clinical trial with PEG-Interferon lambda and ribavirin in chronic hepatitis C virus (HCV) infection.

25 Aug 2010

Pharmasset commences dosing in PSI-7977 Phase 2b study for chronic hepatitis C

Pharmasset, Inc. announced today that dosing has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 200mg QD and 400mg QD in combination with pegylated interferon alfa 2a and ribavirin, the current standard of care (SOC) in patients with HCV genotype 1 who have not been treated previously.

24 Aug 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

Shared needle at school science experiment puts students at risk

Phase 3 REALIZE study shows milestone in treatment development for hepatitis C

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

Bristol-Myers Squibb signs definitive agreement to acquire ZymoGenetics

Teleflex partners with Access Scientific to distribute The PICC WAND vascular access device

Idenix Pharmaceuticals receives clinical hold order from FDA for IDX184, IDX320 programs

DSM, PolyTherics enter agreement for HiPEG IFN alpha-2a product development

Researchers complete INX-189 clinical trials for Hepatitis C virus

Regional Director of WHO Africa warns of impact global financial situation will have on health systems, MDGs

Inhibitex completes INX-189 Phase1a trial for HCV

Unitract Tuberculin syringe clears FDA 510k market clearance

Abbott RealTime HBV assay receives marketing approval from FDA

Media examine floods' impact in Pakistan

Greater clarity on legal implications of testing incapacitated patients for blood-borne viruses needed

Revolutions Medical seeks due recognition for RevVac vacuum operated auto retractable safety syringe

Biomagnetics to acquire Lanzhou New Sunshine Plastics Industry

Biomagnetics Diagnostics to acquire Hubei Tianyuan Chemical

FDA accepts Sanofi Pasteur's Menactra vaccine sBLA for active immunization of infants and toddlers

ZymoGenetics completes enrollment in Phase 2b PEG-IFN lambda clinical trial

Pharmasset commences dosing in PSI-7977 Phase 2b study for chronic hepatitis C

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in